Drug Discovery Today
AUGUST 24, 2022
Togo receives an outstanding achievement award as the first ever country to eliminate four neglected tropical diseases (NTDs) at the 72nd session of the WHO Regional Committee for Africa
Antidote
AUGUST 22, 2022
Online communities have long provided people with the opportunity to connect with others across the globe, and as the internet has become more ubiquitous in our day-to-day lives, their popularity has only increased. Online groups often pop up surrounding a variety of focuses, from gardening to antiquing to listening to a particular podcast — but they have also become an important way for patients to connect with one another.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for ARISTADA Aristada is a drug marketed by Alkermes Inc and is included in two NDAs. It is available from one supplier. There are sixteen patents…. The post New patent for Alkermes Inc drug ARISTADA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
AUGUST 26, 2022
Today’s guest post comes from Chris Dowd, Senior Vice President of Market Development at ConnectiveRx. Chris discusses the benefits of using in-electronic health record (EHR) messaging to communicate formulary information to both healthcare providers and patients during the patient encounter. Click here to learn more about ConnectiveRx’s in-EHR messaging.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Crown Bioscience
AUGUST 25, 2022
Targeted therapies have altered the landscape of cancer treatment across an increasing number of cancer types. While these drugs have significantly benefited many cancer patients, a major ongoing challenge associated with targeted therapies is acquired drug resistance, which is believed to be a key factor in cancer-related deaths. In this post we explore how acquired drug resistance to targeted therapies can be tackled by using in vivo patient-derived xenograft (PDX) models, which are effective
Antidote
AUGUST 24, 2022
Though idiopathic pulmonary fibrosis (IPF) is the most common type of pulmonary fibrosis , it still has no known cause and no known cure. Because it causes scarring of the lungs, IPF can make it difficult to breathe and gets worse over time — meaning researchers are continually searching for breakthroughs that allow for a better understanding of the condition and how best to treat it.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Channels
AUGUST 23, 2022
Our news-laden summer is coming to an end. Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities that I combed from the Drug Channels coastline: Howard Dean attacks patient-unfriendly cost shifting Cancer patients’ views of copay assistance My $0.02 on key specialty pharmacy trends Evidence for biosimilar-to-biosimilar switching Plus, Dr.
Broad Institute
AUGUST 24, 2022
Proteogenomics reveals markers of chemotherapy resistance and outcome in triple negative breast cancer By Tom Ulrich August 24, 2022 Breadcrumb Home News Proteogenomics reveals markers of chemotherapy resistance and outcome in triple negative breast cancer Integrated approach highlights potential therapeutic opportunities for a challenging tumor type By Molly Chiu, Baylor College of Medicine August 24, 2022 NCI )" title="Triple-negative breast cancer cells (blue).
ProRelix Research
AUGUST 23, 2022
Real-World Evidence Studies: Introduction, Purpose, and Data Collection Strategy The first image that comes to mind when one thinks of where safety and efficacy data for a new treatment is […]. The post Real-World Evidence Studies: Introduction, Purpose, and Data Collection Strategy appeared first on ProRelix Research.
Drug Patent Watch
AUGUST 26, 2022
Annual Drug Patent Expirations for NYMALIZE Nymalize is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are five patents protecting…. The post New patent for Azurity drug NYMALIZE appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Channels
AUGUST 22, 2022
Informa Connect’s Copay, Reimbursement and Access Congress. Hybrid Event | October 12-14 in Philadelphia, PA www.informaconnect.com/copay. Exclusive Offer: Be sure to use your exclusive promo COPAYDC to save 10% off* of your registration. An important event for all aspects cost sharing, Copay, Reimbursement and Access Congress is back and better than ever!
Pharma Manufacturing
AUGUST 23, 2022
In a world mired in supply issues, focusing on machine health can provide relief
Policy Prescription
AUGUST 25, 2022
This past June, during a debate in the Senate Health, Education, Labor and Pensions (HELP) Committee, Senator Richard Burr (R-NC), the committee’s Ranking Member, demonstrated that he does not understand very important developments in our nation’s approach to drug regulation and safety. It was almost as if Sen. Burr had fallen asleep over 20 years ago and woke up believing that nothing had changed in the world of drug regulation.
Drug Patent Watch
AUGUST 26, 2022
Annual Drug Patent Expirations for RYALTRIS Ryaltris is a drug marketed by Glenmark Specialty and is included in one NDA. It is available from one supplier. There are twelve patents…. The post New patent for Glenmark Specialty drug RYALTRIS appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Antidote
AUGUST 22, 2022
There are many things that may influence how an individual reacts to a certain drug, medical device, or treatment plan. This can include age, biological sex, disabilities, chronic comorbidities, geographical location, gender identity, race, and ethnic background, and more — all of which should be considered in the medical decision-making process.
Pharma Manufacturing
AUGUST 22, 2022
New drugs with blockbuster potential might not be far from market
Drug & Device Law
AUGUST 22, 2022
Jacob v. Mentor Worldwide, LLC , 40 F.4th 1329 (11th Cir. 2022), is a very peculiar case and will probably leave some plaintiffs wondering if, maybe, they would be better off without their lawyers. The plaintiff in Jacob sued the manufacturer of a Class III, FDA premarket-approved medical device. As almost all our blog’s readers know, that means federal preemption of many, and often all, claims against the manufacturer.
Drug Patent Watch
AUGUST 25, 2022
Annual Drug Patent Expirations for LEVAQUIN Levaquin is a drug marketed by Janssen Pharms and is included in three NDAs. There is one patent protecting this drug and one Paragraph…. The post New patent expiration for Janssen Pharms drug LEVAQUIN appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
AUGUST 25, 2022
Annual Drug Patent Expirations for ENVARSUS+XR Envarsus Xr is a drug marketed by Veloxis Pharms Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Veloxis Pharms drug ENVARSUS XR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 25, 2022
Annual Drug Patent Expirations for RYANODEX Ryanodex is a drug marketed by Eagle Pharms and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Eagle Pharms drug RYANODEX appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for QVAR+80 Qvar 80 is a drug marketed by Teva Branded Pharm and is included in one NDA. There are seven patents protecting this drug. This…. The post New patent for Teva Branded drug QVAR 80 appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for DEFINITY+RT Definity Rt is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are six…. The post New patent for Lantheus Medcl drug DEFINITY RT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for PROAIR+HFA Proair Hfa is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from nine suppliers. There are…. The post New patent for Teva Branded drug PROAIR HFA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for GENOSYL Genosyl is a drug marketed by Vero Biotech and is included in one NDA. There are twenty-one patents protecting this drug. This drug has…. The post New patent for Vero Biotech drug GENOSYL appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for QVAR+REDIHALER Qvar Redihaler is a drug marketed by Norton Waterford and is included in one NDA. It is available from three suppliers. There are eight…. The post New patent for Norton Waterford drug QVAR REDIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for ICLUSIG Iclusig is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from one supplier. There are five…. The post New patent for Takeda Pharms drug ICLUSIG appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for FIRDAPSE Firdapse is a drug marketed by Catalyst Pharms and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Catalyst Pharms drug FIRDAPSE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for SLYND Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are nine patents protecting this drug. SLYND drug…. The post New patent for Exeltis Usa drug SLYND appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for DROSPIRENONE Drospirenone is a drug marketed by Exeltis Usa Inc, Barr, Glenmark Pharms Ltd, Hetero Labs Ltd, Hlthcare, Jubilant Cadista, Mylan Labs Ltd, Watson Labs,…. The post New patent for Exeltis Usa drug DROSPIRENONE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for SCEMBLIX Scemblix is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There is one patent protecting…. The post New patent for Novartis drug SCEMBLIX appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for CABENUVA+KIT Cabenuva Kit is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There are five…. The post New patent for Viiv Hlthcare drug CABENUVA KIT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for QINLOCK Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are seven patents protecting this drug. This drug has…. The post New patent for Deciphera Pharms drug QINLOCK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2022
Annual Drug Patent Expirations for FINTEPLA Fintepla is a drug marketed by Zogenix Inc and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Zogenix Inc drug FINTEPLA appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
113 
Let's personalize your content